Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg raises target price on Spire Healthcare

(Sharecast News) - Analysts at Berenberg raised their target price on private healthcare firm Spire Healthcare 255.0p to 280.0p as it noted that the group's cost savings efforts were "on track". Berenberg said it believes Spire Healthcare to be on track to deliver mid-single-digit revenue growth and £30.0m of cost savings in FY25, which it noted looks "even more credible" after the group announced headcount adjustments in May.

The German bank expects revenue growth to be evenly weighted between H1 and H2, including mid-single-digit growth in hospital revenues and high-single-digit growth in primary care.

Based on management guidance, Berenberg expects the bulk of Spire's cost savings to be realised in H2, and said it assumes a £10.0m hit related to headcount adjustments.

"As we tweak up our cost savings assumptions, adjust finance costs and factor in the sector re-rating from March to now, our price target moves up to 280.0p," said Berenberg, which reiterated its 'buy' rating on the stock.

Berenberg also highlighted that with the stock trading on a 6.9x FY26 enterprise value/underlying earnings ratio for double-digit earnings per share growth, Spire's valuation "looks compelling".

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.